{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:55:28Z","timestamp":1793105728638,"version":"4.5.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s43440-025-00789-4","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T02:32:11Z","timestamp":1759804331000},"page":"1600-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tyrosine kinase 2 inhibitors in the therapy of inflammatory and autoimmune diseases"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4645-4258","authenticated-orcid":false,"given":"Patryk","family":"Rzeczycki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Plust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6821-0086","authenticated-orcid":false,"given":"Paulina","family":"Plewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7240-1079","authenticated-orcid":false,"given":"Ewa","family":"D\u0105browska-\u017bamojcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-1208","authenticated-orcid":false,"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, et al. Autoimmune pathways in mice and humans are blocked by Pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:502.","journal-title":"Sci Transl Med"},{"issue":"13","key":"789_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2217\/imt-2021-0096","volume":"13","author":"M Gonciarz","year":"2021","unstructured":"Gonciarz M, Pawlak-Bu\u015b K, Leszczy\u0144ski P, Owczarek W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy. 2021;13(13):1135\u201350.","journal-title":"Immunotherapy"},{"issue":"1suppl","key":"789_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1177\/12034754221141680","volume":"27","author":"WJ Loo","year":"2023","unstructured":"Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, et al. Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway. J Cutan Med Surg. 2023;27(1suppl):S3\u201324.","journal-title":"J Cutan Med Surg"},{"key":"789_CR4","doi-asserted-by":"publisher","first-page":"884399","DOI":"10.3389\/fimmu.2022.884399","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Li X, Shen R, Wang X, Zhang F, Liu S, et al. Novel small molecule tyrosine kinase 2 pseudokinase ligands block Cytokine-Induced TYK2-Mediated signaling pathways. Front Immunol. 2022;13:884399.","journal-title":"Front Immunol"},{"issue":"5","key":"789_CR5","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","volume":"191","author":"SJ Sohn","year":"2013","unstructured":"Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013;191(5):2205\u201316.","journal-title":"J Immunol"},{"issue":"7","key":"789_CR6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","volume":"47","author":"K Welsch","year":"2017","unstructured":"Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47(7):1096\u2013107.","journal-title":"Eur J Immunol"},{"key":"789_CR7","doi-asserted-by":"crossref","unstructured":"Dragotto M, D\u2019Onghia M, Trovato E, Tognetti L, Rubegni P, Calabrese L. Therapeutic potential of targeting the JAK\/STAT pathway in psoriasis: focus on TYK2 Inhibition. J Clin Med. 2024;13(11).","DOI":"10.3390\/jcm13113091"},{"issue":"10","key":"789_CR8","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1084\/jem.20140280","volume":"212","author":"AY Kreins","year":"2015","unstructured":"Kreins AY, Ciancanelli MJ, Okada S, Kong XF, Ram\u00edrez-Alejo N, Kilic SS, et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015;212(10):1641\u201362.","journal-title":"J Exp Med"},{"issue":"1","key":"789_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s10875-019-00713-5","volume":"40","author":"SA Sarrafzadeh","year":"2020","unstructured":"Sarrafzadeh SA, Mahloojirad M, Casanova JL, Badalzadeh M, Bustamante J, Boisson-Dupuis S, et al. A new patient with inherited TYK2 deficiency. J Clin Immunol. 2020;40(1):232\u20135.","journal-title":"J Clin Immunol"},{"issue":"5","key":"789_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","volume":"25","author":"Y Minegishi","year":"2006","unstructured":"Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25(5):745\u201355.","journal-title":"Immunity"},{"issue":"8","key":"789_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3899\/jrheum.081160","volume":"36","author":"A Hellquist","year":"2009","unstructured":"Hellquist A, J\u00e4rvinen TM, Koskenmies S, Zucchelli M, Orsmark-Pietras C, Berglind L, et al. Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol. 2009;36(8):1631\u20138.","journal-title":"J Rheumatol"},{"issue":"4","key":"789_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","volume":"20","author":"E Morand","year":"2024","unstructured":"Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2024;20(4):232\u201340.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"789_CR13","doi-asserted-by":"publisher","first-page":"e0122271","DOI":"10.1371\/journal.pone.0122271","volume":"10","author":"D Diogo","year":"2015","unstructured":"Diogo D, Bastarache L, Liao KP, Graham RR, Fulton RS, Greenberg JD, et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE. 2015;10(4):e0122271.","journal-title":"PLoS ONE"},{"issue":"8","key":"789_CR14","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/annrheumdis-2019-215062","volume":"78","author":"T Motegi","year":"2019","unstructured":"Motegi T, Kochi Y, Matsuda K, Kubo M, Yamamoto K, Momozawa Y. Identification of rare coding variants in. Ann Rheum Dis. 2019;78(8):1062\u20139.","journal-title":"Ann Rheum Dis"},{"key":"789_CR15","doi-asserted-by":"publisher","first-page":"111238","DOI":"10.1016\/j.intimp.2023.111238","volume":"126","author":"X Cui","year":"2024","unstructured":"Cui X, Teng Y, Hu Y, Li Q, Pei H, Yang Z. Therapeutic potential of a synthetic dual JAK1\/TYK2 inhibitor in inflammatory bowel disease. Int Immunopharmacol. 2024;126:111238.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"789_CR16","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/ibd\/izab135","volume":"27","author":"S Danese","year":"2021","unstructured":"Danese S, Peyrin-Biroulet L. Selective tyrosine kinase 2 Inhibition for treatment of inflammatory bowel disease: new hope on the rise. Inflamm Bowel Dis. 2021;27(12):2023\u201330.","journal-title":"Inflamm Bowel Dis"},{"issue":"13","key":"789_CR17","doi-asserted-by":"publisher","first-page":"e2422172122","DOI":"10.1073\/pnas.2422172122","volume":"122","author":"TP Molitor","year":"2025","unstructured":"Molitor TP, Hayashi G, Lin MY, Dunn CJ, Peterson NG, Poston RG, et al. Central TYK2 Inhibition identifies TYK2 as a key neuroimmune modulator. Proc Natl Acad Sci U S A. 2025;122(13):e2422172122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"789_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ejhg.2009.195","volume":"18","author":"IL Mero","year":"2010","unstructured":"Mero IL, Lorentzen AR, Ban M, Smestad C, Celius EG, Aarseth JH, et al. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur J Hum Genet. 2010;18(4):502\u20134.","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"789_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/10600280231153863","volume":"58","author":"TM Truong","year":"2024","unstructured":"Truong TM, Pathak GN, Singal A, Taranto V, Rao BK. Deucravacitinib: the first FDA-Approved oral TYK2 inhibitor for moderate to severe plaque psoriasis. Ann Pharmacother. 2024;58(4):416\u201327.","journal-title":"Ann Pharmacother"},{"key":"789_CR20","doi-asserted-by":"publisher","first-page":"1437512","DOI":"10.3389\/fimmu.2024.1437512","volume":"15","author":"B Johnson","year":"2024","unstructured":"Johnson B, Cheng L, Koenitzer J, Catlett IM, Schafer P. Nonclinical evaluations of Deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways. Front Immunol. 2024;15:1437512.","journal-title":"Front Immunol"},{"key":"789_CR21","doi-asserted-by":"publisher","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","volume":"189","author":"R Roskoski","year":"2023","unstructured":"Roskoski R. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023;189:106642.","journal-title":"Pharmacol Res"},{"issue":"6","key":"789_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"789_CR23","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/rheumatology\/keae580","volume":"64","author":"A Kavanaugh","year":"2025","unstructured":"Kavanaugh A, Coates LC, Mease PJ, Nowak M, Hippeli L, Lehman T, et al. Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial. Rheumatology (Oxford). 2025;64(5):2557\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"789_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/24755303231201336","volume":"8","author":"P Kingston","year":"2023","unstructured":"Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023;8(4):156\u201365.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"789_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a tyrosine kinase 2 Inhibitor, in systemic lupus erythematosus: A phase II, Randomized, Double-Blind, Placebo-Controlled trial. Arthritis Rheumatol. 2023;75(2):242\u201352.","journal-title":"Arthritis Rheumatol"},{"key":"789_CR26","doi-asserted-by":"publisher","first-page":"1217147","DOI":"10.3389\/fmed.2023.1217147","volume":"10","author":"D Nikolopoulos","year":"2023","unstructured":"Nikolopoulos D, Parodis I. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 Inhibition. Front Med (Lausanne). 2023;10:1217147.","journal-title":"Front Med (Lausanne)"},{"issue":"Suppl 1","key":"789_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.31138\/mjr.231123.jia","volume":"35","author":"GS Moysidou","year":"2024","unstructured":"Moysidou GS, Dara A. JAK Inhibition as a potential treatment target in systemic lupus erythematosus. Mediterr J Rheumatol. 2024;35(Suppl 1):37\u201344.","journal-title":"Mediterr J Rheumatol"},{"key":"789_CR28","doi-asserted-by":"crossref","unstructured":"Satoh-Kanda Y, Nakayamada S, Tanaka Y. Fine-tuning SLE treatment: the potential of selective TYK2 Inhibition. RMD Open. 2024;10(4).","DOI":"10.1136\/rmdopen-2024-005072"},{"key":"789_CR29","doi-asserted-by":"crossref","unstructured":"D\u2019Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K et al. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 2025;19(6).","DOI":"10.1093\/ecco-jcc\/jjaf080"},{"key":"789_CR30","doi-asserted-by":"crossref","unstructured":"Sharip MT, Raine T, Noor NM. Hit the road, JAK: is there still hope left for TYK2 Inhibition in IBD? J Crohns Colitis. 2025;19(6).","DOI":"10.1093\/ecco-jcc\/jjaf088"},{"issue":"8","key":"789_CR31","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.42519","volume":"75","author":"P Mease","year":"2023","unstructured":"Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, et al. Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: A phase IIb randomized controlled trial. Arthritis Rheumatol. 2023;75(8):1370\u201380.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"789_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajd.14391","volume":"66","author":"MG Haggett","year":"2025","unstructured":"Haggett MG, Lee S, Lai FYX. A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease. Australas J Dermatol. 2025;66(1):1\u201313.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"789_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/ijd.15605","volume":"61","author":"CE Jo","year":"2022","unstructured":"Jo CE, Gooderham M, Beecker J. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. Int J Dermatol. 2022;61(2):139\u201347.","journal-title":"Int J Dermatol"},{"key":"789_CR34","doi-asserted-by":"crossref","unstructured":"Rusi\u00f1ol L, Puig L. Tyk2 targeting in Immune-Mediated inflammatory diseases. Int J Mol Sci. 2023;24(4).","DOI":"10.3390\/ijms24043391"},{"key":"789_CR35","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023;21(10):2616-28.e7.","DOI":"10.1016\/j.cgh.2022.12.029"},{"issue":"10","key":"789_CR36","first-page":"1409","volume":"19","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Augustin M, Baraliakos X, Kr\u00f6nke G, Schneider M, Schreiber S, et al. TYK2 Inhibition and its potential in the treatment of chronic inflammatory immune diseases. J Dtsch Dermatol Ges. 2021;19(10):1409\u201320.","journal-title":"J Dtsch Dermatol Ges"},{"key":"789_CR37","doi-asserted-by":"publisher","unstructured":"Wang J, Lomakin IB, Batista VS, Bunick CG. A Triple-Action inhibitory mechanism of allosteric TYK2-Specific inhibitors. J Invest Dermatol. 2025;S0022-202X(25)00474-9. Online ahead of print. https:\/\/doi.org\/10.1016\/j.jid.2025.04.025","DOI":"10.1016\/j.jid.2025.04.025"},{"issue":"4","key":"789_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"M Nogueira","year":"2020","unstructured":"Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341\u201352.","journal-title":"Drugs"},{"key":"789_CR39","doi-asserted-by":"crossref","unstructured":"W\u00f6ss K, Simonovi\u0107 N, Strobl B, Macho-Maschler S, M\u00fcller M. TYK2: an upstream kinase of stats in cancer. Cancers (Basel). 2019;11(11).","DOI":"10.3390\/cancers11111728"},{"key":"789_CR40","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.2147\/JIR.S380686","volume":"15","author":"L Shang","year":"2022","unstructured":"Shang L, Cao J, Zhao S, Zhang J, He Y. TYK2 in immune responses and treatment of psoriasis. J Inflamm Res. 2022;15:5373\u201385.","journal-title":"J Inflamm Res"},{"key":"789_CR41","doi-asserted-by":"publisher","first-page":"104840","DOI":"10.1016\/j.ebiom.2023.104840","volume":"97","author":"LT Jensen","year":"2023","unstructured":"Jensen LT, Attfield KE, Feldmann M, Fugger L. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. EBioMedicine. 2023;97:104840.","journal-title":"EBioMedicine"},{"issue":"4","key":"789_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13543776.2022.2026927","volume":"32","author":"F de Turiso","year":"2022","unstructured":"Gonzalez Lopez, de Turiso F, Guckian K. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019\u20132021). Expert Opin Ther Pat. 2022;32(4):365\u201379.","journal-title":"Expert Opin Ther Pat"},{"key":"789_CR43","doi-asserted-by":"publisher","unstructured":"Mehrotra S, Sano Y, Halkowycz P, Wilson E, Durairaj C, Kong KF et al. Pharmacological characterization of Zasocitinib (TAK-279): an oral, highly selective, and potent allosteric TYK2 inhibitor. J Invest Dermatol. 2025;S0022-202X(25)00531-7. Online ahead of print. https:\/\/doi.org\/10.1016\/j.jid.2025.05.014","DOI":"10.1016\/j.jid.2025.05.014"},{"issue":"20","key":"789_CR44","doi-asserted-by":"publisher","first-page":"14335","DOI":"10.1021\/acs.jmedchem.3c01373","volume":"66","author":"E Breinlinger","year":"2023","unstructured":"Breinlinger E, Van Epps S, Friedman M, Argiriadi M, Chien E, Chhor G, et al. Targeting the tyrosine kinase 2 (TYK2) pseudokinase domain: discovery of the selective TYK2 inhibitor ABBV-712. J Med Chem. 2023;66(20):14335\u201356.","journal-title":"J Med Chem"},{"key":"789_CR45","doi-asserted-by":"publisher","first-page":"117932","DOI":"10.1016\/j.bmc.2024.117932","volume":"114","author":"O Mammoliti","year":"2024","unstructured":"Mammoliti O, Menet C, Cottereaux C, Blanc J, De Blieck A, Coti G, et al. Design of a potent and selective dual JAK1\/TYK2 inhibitor. Bioorg Med Chem. 2024;114:117932.","journal-title":"Bioorg Med Chem"},{"key":"789_CR46","doi-asserted-by":"publisher","first-page":"129083","DOI":"10.1016\/j.bmcl.2022.129083","volume":"79","author":"JY Kato","year":"2023","unstructured":"Kato JY, Korenaga S, Iwakura M. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor. Bioorg Med Chem Lett. 2023;79:129083.","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"789_CR47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","volume":"13","author":"M Karaghiosoff","year":"2000","unstructured":"Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity. 2000;13(4):549\u201360.","journal-title":"Immunity"},{"issue":"9","key":"789_CR48","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1089\/jir.2023.0039","volume":"43","author":"EV Mesev","year":"2023","unstructured":"Mesev EV, Guare EG, Ploss A, Toettcher JE. Synthetic heterodimers of type III interferon receptors require TYK2 for STAT activation. J Interferon Cytokine Res. 2023;43(9):414\u201326.","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"789_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/1744666X.2022.2008240","volume":"18","author":"A Abduelmula","year":"2022","unstructured":"Abduelmula A, Gooderham MJ. TYK2 inhibition: changing the treatment landscape for psoriasis? Expert Rev Clin Immunol. 2022;18(3):185\u20137.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"789_CR50","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1248\/bpb.b21-00609","volume":"44","author":"R Muromoto","year":"2021","unstructured":"Muromoto R, Shimoda K, Oritani K, Matsuda T. Therapeutic advantage of Tyk2 Inhibition for treating autoimmune and chronic inflammatory diseases. Biol Pharm Bull. 2021;44(11):1585\u201392.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"789_CR51","doi-asserted-by":"publisher","first-page":"e13671","DOI":"10.1111\/pai.13671","volume":"33","author":"G Lv","year":"2022","unstructured":"Lv G, Sun G, Wu P, Du X, Zeng T, Wen W, et al. Novel mutations of TYK2 leading to divergent clinical phenotypes. Pediatr Allergy Immunol. 2022;33(1):e13671.","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"789_CR52","doi-asserted-by":"publisher","first-page":"e20200425","DOI":"10.1590\/1678-4685-gmb-2020-0425","volume":"44","author":"FM Pellenz","year":"2021","unstructured":"Pellenz FM, Dieter C, Lemos NE, Bauer AC, Souza BM, Crispim D. Association of TYK2 polymorphisms with autoimmune diseases: A comprehensive and updated systematic review with meta-analysis. Genet Mol Biol. 2021;44(2):e20200425.","journal-title":"Genet Mol Biol"},{"issue":"1","key":"789_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273\u201387.","journal-title":"Immunol Rev"},{"issue":"4","key":"789_CR54","doi-asserted-by":"publisher","first-page":"e15080","DOI":"10.1111\/exd.15080","volume":"33","author":"KN Stolte","year":"2024","unstructured":"Stolte KN, Mesas-Fern\u00e1ndez A, Meier K, Klein EK, Dommisch H, Ghoreschi K, et al. TYK2 Inhibition with Deucravacitinib ameliorates erosive oral lichen planus. Exp Dermatol. 2024;33(4):e15080.","journal-title":"Exp Dermatol"},{"issue":"1","key":"789_CR55","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41467-024-45573-9","volume":"15","author":"K Mine","year":"2024","unstructured":"Mine K, Nagafuchi S, Akazawa S, Abiru N, Mori H, Kurisaki H, et al. TYK2 signaling promotes the development of autoreactive CD8. Nat Commun. 2024;15(1):1337.","journal-title":"Nat Commun"},{"issue":"6","key":"789_CR56","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1093\/rheumatology\/keaf019","volume":"64","author":"T Fukasawa","year":"2025","unstructured":"Fukasawa T, Yoshizaki-Ogawa A, Yoshizaki A, Sato S. The effects of Deucravacitinib on three cases of systemic sclerosis associated with psoriasis. Rheumatology (Oxford). 2025;64(6):4067\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"789_CR57","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00018-025-05625-9","volume":"82","author":"A Karjalainen","year":"2025","unstructured":"Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M, et al. Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions. Cell Mol Life Sci. 2025;82(1):98.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"789_CR58","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.4049\/jimmunol.181.3.2071","volume":"181","author":"R Nakamura","year":"2008","unstructured":"Nakamura R, Shibata K, Yamada H, Shimoda K, Nakayama K, Yoshikai Y. Tyk2-signaling plays an important role in host defense against Escherichia coli through IL-23-induced IL-17 production by gammadelta T cells. J Immunol. 2008;181(3):2071\u20135.","journal-title":"J Immunol"},{"issue":"1","key":"789_CR59","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4049\/jimmunol.1003244","volume":"187","author":"M Ishizaki","year":"2011","unstructured":"Ishizaki M, Akimoto T, Muromoto R, Yokoyama M, Ohshiro Y, Sekine Y, et al. Involvement of tyrosine kinase-2 in both the IL-12\/Th1 and IL-23\/Th17 axes in vivo. J Immunol. 2011;187(1):181\u20139.","journal-title":"J Immunol"},{"issue":"6","key":"789_CR60","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/14740338.2024.2351462","volume":"23","author":"L Potestio","year":"2024","unstructured":"Potestio L, Tommasino N, Lauletta G, Feo F, Ruggiero A, Martora F, et al. Efficacy and safety of Deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2024;23(6):677\u201385.","journal-title":"Expert Opin Drug Saf"},{"issue":"363","key":"789_CR61","doi-asserted-by":"publisher","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149.","journal-title":"Sci Transl Med"},{"issue":"45","key":"789_CR62","doi-asserted-by":"publisher","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","volume":"290","author":"X Min","year":"2015","unstructured":"Min X, Ungureanu D, Maxwell S, Hammar\u00e9n H, Thibault S, Hillert EK, et al. Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). J Biol Chem. 2015;290(45):27261\u201370.","journal-title":"J Biol Chem"},{"key":"789_CR63","first-page":"1563","volume":"19","author":"KA Ullrich","year":"2020","unstructured":"Ullrich KA, Schulze LL, Paap EM, M\u00fcller TM, Neurath MF, Zundler S. Immunology of IL-12: an update on functional activities and implications for disease. EXCLI J. 2020;19:1563\u201389.","journal-title":"EXCLI J"},{"key":"789_CR64","doi-asserted-by":"publisher","first-page":"110434","DOI":"10.1016\/j.intimp.2023.110434","volume":"121","author":"L Deng","year":"2023","unstructured":"Deng L, Wan L, Liao T, Wang L, Wang J, Wu X, et al. Recent progress on tyrosine kinase 2 JH2 inhibitors. Int Immunopharmacol. 2023;121:110434.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"789_CR65","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.str.2024.07.010","volume":"32","author":"H Chen","year":"2024","unstructured":"Chen H, Ge X, Li C, Zeng J, Wang X. Structure and assembly of the human IL-12 signaling complex. Structure. 2024;32(10):1640\u2013e515.","journal-title":"Structure"},{"issue":"1","key":"789_CR66","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1084\/jem.181.1.399","volume":"181","author":"CM Bacon","year":"1995","unstructured":"Bacon CM, McVicar DW, Ortaldo JR, Rees RC, O\u2019Shea JJ, Johnston JA. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med. 1995;181(1):399\u2013404.","journal-title":"J Exp Med"},{"issue":"10","key":"789_CR67","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.4049\/jimmunol.162.10.6255","volume":"162","author":"JJ Bright","year":"1999","unstructured":"Bright JJ, Du C, Sriram S. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol. 1999;162(10):6255\u201362.","journal-title":"J Immunol"},{"issue":"1","key":"789_CR68","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/immu.200390027","volume":"33","author":"N Sugimoto","year":"2003","unstructured":"Sugimoto N, Nakahira M, Ahn HJ, Micallef M, Hamaoka T, Kurimoto M, et al. Differential requirements for JAK2 and TYK2 in T cell proliferation and IFN-gamma production induced by IL-12 alone or together with IL-18. Eur J Immunol. 2003;33(1):243\u201351.","journal-title":"Eur J Immunol"},{"issue":"14","key":"789_CR69","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1091\/mbc.E14-12-1645","volume":"27","author":"DM Floss","year":"2016","unstructured":"Floss DM, Kl\u00f6cker T, Schr\u00f6der J, Lamertz L, Mrotzek S, Strobl B, et al. Defining the functional binding sites of Interleukin 12 receptor \u03b21 and Interleukin 23 receptor to Janus kinases. Mol Biol Cell. 2016;27(14):2301\u201316.","journal-title":"Mol Biol Cell"},{"issue":"5","key":"789_CR70","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00011-020-01339-9","volume":"69","author":"AIK Abdo","year":"2020","unstructured":"Abdo AIK, Tye GJ. Interleukin 23 and autoimmune diseases: current and possible future therapies. Inflamm Res. 2020;69(5):463\u201380.","journal-title":"Inflamm Res"},{"issue":"9","key":"789_CR71","first-page":"3214","volume":"16","author":"B Strobl","year":"2011","unstructured":"Strobl B, Stoiber D, Sexl V, Mueller M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci (Landmark Ed). 2011;16(9):3214\u201332.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"789_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1432-1033.1994.tb19010.x","volume":"223","author":"G Barbieri","year":"1994","unstructured":"Barbieri G, Velazquez L, Scrobogna M, Fellous M, Pellegrini S. Activation of the protein tyrosine kinase tyk2 by interferon alpha\/beta. Eur J Biochem. 1994;223(2):427\u201335.","journal-title":"Eur J Biochem"},{"issue":"16","key":"789_CR73","doi-asserted-by":"publisher","first-page":"8991","DOI":"10.1073\/pnas.160130297","volume":"97","author":"TC Yeh","year":"2000","unstructured":"Yeh TC, Dondi E, Uze G, Pellegrini S. A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc Natl Acad Sci U S A. 2000;97(16):8991\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"789_CR74","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","volume":"193","author":"MG Works","year":"2014","unstructured":"Works MG, Yin F, Yin CC, Yiu Y, Shew K, Tran TT, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis. J Immunol. 2014;193(7):3278\u201387.","journal-title":"J Immunol"},{"key":"789_CR75","doi-asserted-by":"publisher","first-page":"1161067","DOI":"10.3389\/fimmu.2023.1161067","volume":"14","author":"V Carlini","year":"2023","unstructured":"Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L, et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023;14:1161067.","journal-title":"Front Immunol"},{"issue":"6","key":"789_CR76","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1189\/jlb.0212101","volume":"92","author":"MM Elloso","year":"2012","unstructured":"Elloso MM, Gomez-Angelats M, Fourie AM. Targeting the Th17 pathway in psoriasis. J Leukoc Biol. 2012;92(6):1187\u201397.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"789_CR77","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2006-11-059246","volume":"110","author":"N Tokumasa","year":"2007","unstructured":"Tokumasa N, Suto A, Kagami S, Furuta S, Hirose K, Watanabe N, et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood. 2007;110(2):553\u201360.","journal-title":"Blood"},{"issue":"3","key":"789_CR78","doi-asserted-by":"publisher","first-page":"236","DOI":"10.30699\/IJP.2019.94878.1934","volume":"14","author":"S Mohammadi","year":"2019","unstructured":"Mohammadi S, Sedighi S, Memarian A. IL-17 is aberrantly overexpressed among Under-treatment. Iran J Pathol. 2019;14(3):236\u201342.","journal-title":"Iran J Pathol"},{"issue":"9","key":"789_CR79","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00403-018-1858-0","volume":"310","author":"Q Yin","year":"2018","unstructured":"Yin Q, Wu LC, Zheng L, Han MY, Hu LY, Zhao PP, et al. Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis. Arch Dermatol Res. 2018;310(9):711\u201328.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"789_CR80","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1086\/428480","volume":"76","author":"S Sigurdsson","year":"2005","unstructured":"Sigurdsson S, Nordmark G, G\u00f6ring HH, Lindroos K, Wiman AC, Sturfelt G, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005;76(3):528\u201337.","journal-title":"Am J Hum Genet"},{"key":"789_CR81","doi-asserted-by":"crossref","unstructured":"Parodis I, Long X, Karlsson MCI, Huang X. B cell tolerance and targeted therapies in SLE. J Clin Med. 2023;12(19).","DOI":"10.3390\/jcm12196268"},{"issue":"1","key":"789_CR82","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12013-014-9903-x","volume":"70","author":"G Tian","year":"2014","unstructured":"Tian G, Li JL, Wang DG, Zhou D. Targeting IL-10 in auto-immune diseases. Cell Biochem Biophys. 2014;70(1):37\u201349.","journal-title":"Cell Biochem Biophys"},{"issue":"11","key":"789_CR83","doi-asserted-by":"publisher","first-page":"103649","DOI":"10.1016\/j.autrev.2024.103649","volume":"23","author":"C Ramakrishna","year":"2024","unstructured":"Ramakrishna C, Mason A, Edwards CJ. Tyrosine kinase 2 inhibitors in autoimmune diseases. Autoimmun Rev. 2024;23(11):103649.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"789_CR84","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/17512433.2023.2219054","volume":"16","author":"S Elyoussfi","year":"2023","unstructured":"Elyoussfi S, Rane SS, Eyre S, Warren RB. TYK2 as a novel therapeutic target in psoriasis. Expert Rev Clin Pharmacol. 2023;16(6):549\u201358.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"789_CR85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/intimm\/dxt062","volume":"26","author":"M Ishizaki","year":"2014","unstructured":"Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M, et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol. 2014;26(5):257\u201367.","journal-title":"Int Immunol"},{"key":"789_CR86","doi-asserted-by":"publisher","first-page":"108513","DOI":"10.1016\/j.clim.2020.108513","volume":"218","author":"H Dai","year":"2020","unstructured":"Dai H, Adamopoulos IE. Psoriatic arthritis under the influence of IFN\u03b3. Clin Immunol. 2020;218:108513.","journal-title":"Clin Immunol"},{"issue":"1","key":"789_CR87","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1038\/s41598-018-25282-2","volume":"8","author":"C Enerb\u00e4ck","year":"2018","unstructured":"Enerb\u00e4ck C, Sandin C, Lambert S, Zawistowski M, Stuart PE, Verma D, et al. The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4\u2009+\u2009and CD8\u2009+\u2009memory T-cells. Sci Rep. 2018;8(1):7043.","journal-title":"Sci Rep"},{"key":"789_CR88","doi-asserted-by":"crossref","unstructured":"Rane SS, Elyoussfi S, Shellard E, Eyre S, Warren RB. Characterising a novel therapeutic target for psoriasis, TYK2, using functional genomics. Int J Mol Sci. 2024;25(23).","DOI":"10.3390\/ijms252313229"},{"key":"789_CR89","doi-asserted-by":"crossref","unstructured":"Patel HA, Revankar RR, Pedroza ST, Graham S, Feldman SR. The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options. Int J Mol Sci. 2023;24(15).","DOI":"10.3390\/ijms241512310"},{"issue":"2","key":"789_CR90","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/187152812800392805","volume":"11","author":"E Toussirot","year":"2012","unstructured":"Toussirot E. The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11(2):159\u201368.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"789_CR91","doi-asserted-by":"publisher","first-page":"637829","DOI":"10.3389\/fimmu.2021.637829","volume":"12","author":"C Schinocca","year":"2021","unstructured":"Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, et al. Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829.","journal-title":"Front Immunol"},{"issue":"5\u20136","key":"789_CR92","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.micinf.2019.06.009","volume":"21","author":"E Bianchi","year":"2019","unstructured":"Bianchi E, Rogge L. The IL-23\/IL-17 pathway in human chronic inflammatory diseases - new insight from genetics and targeted therapies. Microbes Infect. 2019;21(5\u20136):246\u201353.","journal-title":"Microbes Infect"},{"key":"789_CR93","doi-asserted-by":"publisher","first-page":"109228","DOI":"10.1016\/j.intimp.2022.109228","volume":"112","author":"X Chen","year":"2022","unstructured":"Chen X, Wu Q, Cao X, Yang Y, Gong Z, Ren T, et al. Menthone inhibits type-I interferon signaling by promoting Tyk2 ubiquitination to relieve local inflammation of rheumatoid arthritis. Int Immunopharmacol. 2022;112:109228.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"789_CR94","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/intimm\/dxr057","volume":"23","author":"M Ishizaki","year":"2011","unstructured":"Ishizaki M, Muromoto R, Akimoto T, Ohshiro Y, Takahashi M, Sekine Y, et al. Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Int Immunol. 2011;23(9):575\u201382.","journal-title":"Int Immunol"},{"key":"789_CR95","doi-asserted-by":"publisher","first-page":"104951","DOI":"10.1016\/j.yexmp.2024.104951","volume":"141","author":"F Cacciapaglia","year":"2025","unstructured":"Cacciapaglia F, Perniola S, Stano S, Venerito V, Natuzzi D, Bizzoca R, et al. Modulation of IL-6 receptor\/STAT3 downstream signaling in rheumatoid arthritis patients. Exp Mol Pathol. 2025;141:104951.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"789_CR96","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther. 2023;8(1):68.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"789_CR97","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.4049\/jimmunol.169.5.2643","volume":"169","author":"T Itoh","year":"2002","unstructured":"Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol. 2002;169(5):2643\u20137.","journal-title":"J Immunol"},{"key":"789_CR98","first-page":"e928455","volume":"27","author":"Y Peng","year":"2021","unstructured":"Peng Y, Chen B, Sheng X, Qian Y. Polymorphisms in IRF5 and TYK2 genes are associated with rheumatoid arthritis in a Chinese Han population. Med Sci Monit. 2021;27:e928455.","journal-title":"Med Sci Monit"},{"issue":"8","key":"789_CR99","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1136\/annrheumdis-2021-221754","volume":"81","author":"S Saevarsdottir","year":"2022","unstructured":"Saevarsdottir S, Stefansdottir L, Sulem P, Thorleifsson G, Ferkingstad E, Rutsdottir G, et al. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Ann Rheum Dis. 2022;81(8):1085\u201395.","journal-title":"Ann Rheum Dis"},{"key":"789_CR100","doi-asserted-by":"crossref","unstructured":"Alexander M, Luo Y, Raimondi G, O\u2019Shea JJ, Gadina M. Jakinibs of all trades: inhibiting cytokine signaling in Immune-Mediated pathologies. Pharmaceuticals (Basel). 2021;15(1).","DOI":"10.3390\/ph15010048"},{"issue":"2","key":"789_CR101","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","volume":"29","author":"X He","year":"2019","unstructured":"He X, Chen X, Zhang H, Xie T, Ye XY. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015\u20132018). Expert Opin Ther Pat. 2019;29(2):137\u201349.","journal-title":"Expert Opin Ther Pat"},{"key":"789_CR102","doi-asserted-by":"publisher","first-page":"1264667","DOI":"10.3389\/fmed.2023.1264667","volume":"10","author":"J Qiu","year":"2023","unstructured":"Qiu J, Liu J, Liu W, Lin F, Shi N. The efficacy and safety of tyrosine kinase 2 inhibitor Deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2023;10:1264667.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"789_CR103","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","volume":"161","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, et al. Safety and efficacy of Deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an Open-Label extension of randomized clinical trials. JAMA Dermatol. 2025;161(1):56\u201366.","journal-title":"JAMA Dermatol"},{"key":"789_CR104","doi-asserted-by":"crossref","unstructured":"Vogl C, Flatt T, Fuhrmann T, Hofmann E, Wallner B, Stiefvater R et al. Transcriptome analysis reveals a major impact of JAK protein tyrosine Kinease 2 (Tyk2) on the expression of interferon - responsive and metabolic genes. BMC Genomics. 2010;11.","DOI":"10.1186\/1471-2164-11-199"},{"key":"789_CR105","doi-asserted-by":"crossref","unstructured":"Mallik SB, Tandon A, Kuriappan JA, Kapure JS, Halle M, Iyer A. Topical selective TYk2 Inhibition attenuates inflammation and clinical symptoms in a mouse Moel of human psoriasis. JI. 2023;210:16605.","DOI":"10.4049\/jimmunol.210.Supp.166.05"},{"issue":"5","key":"789_CR106","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tips.2022.02.008","volume":"43","author":"OH Nielsen","year":"2022","unstructured":"Nielsen OH, Boye TL, Chakravarti D, Gubatan J. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends Pharmacol Sci. 2022;43(5):424\u201336.","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"789_CR107","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1007\/s13555-024-01262-5","volume":"14","author":"IM Catlett","year":"2024","unstructured":"Catlett IM, Gao L, Hu Y, Banerjee S, Krueger JG. Pharmacodynamic response to Deucravacitinib, an Oral, Selective, allosteric TYK2 Inhibitor, in a Global, phase 2, Randomized, Double-Blind, Placebo-Controlled psoriasis trial. Dermatol Ther (Heidelb). 2024;14(10):2827\u201339.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"789_CR108","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, et al. Selectivity profile of the tyrosine kinase 2 inhibitor Deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763\u201376.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"789_CR109","doi-asserted-by":"publisher","first-page":"108224","DOI":"10.1016\/j.compbiolchem.2024.108224","volume":"113","author":"Y Bao","year":"2024","unstructured":"Bao Y, Xu R, Guo J. The multiple-action allosteric Inhibition of TYK2 by deucravacitinib: insights from computational simulations. Comput Biol Chem. 2024;113:108224.","journal-title":"Comput Biol Chem"},{"issue":"1","key":"789_CR110","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12026-025-09649-y","volume":"73","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang C, Liang J, Liu Y, Xu B, Li C. Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria. Immunol Res. 2025;73(1):92.","journal-title":"Immunol Res"},{"issue":"8","key":"789_CR111","doi-asserted-by":"publisher","first-page":"e13855","DOI":"10.1111\/srt.13855","volume":"30","author":"C Hu","year":"2024","unstructured":"Hu C, Han X, Cui Y, Zhang Y, Cheng Y. Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta-analysis. Skin Res Technol. 2024;30(8):e13855.","journal-title":"Skin Res Technol"},{"issue":"6","key":"789_CR112","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","volume":"149","author":"IM Catlett","year":"2022","unstructured":"Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 Inhibition with Deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010\u2013e208.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"789_CR113","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.13435","volume":"16","author":"IM Catlett","year":"2023","unstructured":"Catlett IM, Aras U, Hansen L, Liu Y, Bei D, Girgis IG, et al. First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023;16(1):151\u201364.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"789_CR114","doi-asserted-by":"publisher","first-page":"103440","DOI":"10.1016\/j.autrev.2023.103440","volume":"22","author":"L Ma","year":"2023","unstructured":"Ma L, Peng L, Zhao J, Bai W, Jiang N, Zhang S, et al. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2023;22(12):103440.","journal-title":"Autoimmun Rev"},{"issue":"4\u20135","key":"789_CR115","first-page":"225","volume":"35","author":"M Kaur","year":"2024","unstructured":"Kaur M, Misra S. Deucravacitinib: moderate-to-severe plaque psoriasis preventable? J Basic Clin Physiol Pharmacol. 2024;35(4\u20135):225\u201330.","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"1","key":"789_CR116","doi-asserted-by":"publisher","first-page":"2154122","DOI":"10.1080\/09546634.2022.2154122","volume":"34","author":"T Estevinho","year":"2023","unstructured":"Estevinho T, L\u00e9 AM, Torres T. Deucravacitinib in the treatment of psoriasis. J Dermatolog Treat. 2023;34(1):2154122.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"789_CR117","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1346-8138.16740","volume":"50","author":"S Imafuku","year":"2023","unstructured":"Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. J Dermatol. 2023;50(5):588\u201395.","journal-title":"J Dermatol"},{"issue":"17","key":"789_CR118","first-page":"1671","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM, Deucravacitinib. First Approval Drugs. 2022;82(17):1671\u20139.","journal-title":"First Approval Drugs"},{"issue":"1","key":"789_CR119","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and Apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program fOr evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"789_CR120","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/17460441.2023.2246880","volume":"18","author":"G Coscarella","year":"2023","unstructured":"Coscarella G, Malvaso D, Mannino M, Caldarola G, Fossati B, De Simone C, et al. The preclinical discovery and development of Deucravacitinib for the treatment of psoriasis. Expert Opin Drug Discov. 2023;18(11):1201\u20138.","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"789_CR121","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","volume":"23","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23(6):813\u201322.","journal-title":"Am J Clin Dermatol"},{"key":"789_CR122","doi-asserted-by":"crossref","unstructured":"Bang CH, Park CJ, Kim YS. The expanding therapeutic potential of Deucravacitinib beyond psoriasis: a narrative review. J Clin Med. 2025;14(5).","DOI":"10.3390\/jcm14051745"},{"issue":"9","key":"789_CR123","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/art.42921","volume":"76","author":"O FitzGerald","year":"2024","unstructured":"FitzGerald O, Gladman DD, Mease PJ, Ritchlin C, Smolen JS, Gao L, et al. Phase 2 trial of Deucravacitinib in psoriatic arthritis: biomarkers associated with disease Activity, Pharmacodynamics, and clinical responses. Arthritis Rheumatol. 2024;76(9):1397\u2013407.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"789_CR124","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13543784.2023.2207737","volume":"32","author":"F Caso","year":"2023","unstructured":"Caso F, Costa L, Triggianese P, Maione F, Bertolini N, Vastarella M, et al. Recent developments for new investigational JAK inhibitors in psoriatic arthritis. Expert Opin Investig Drugs. 2023;32(5):361\u201371.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"789_CR125","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/13543784.2023.2264172","volume":"32","author":"S Nakayamada","year":"2023","unstructured":"Nakayamada S, Tanaka Y. Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now? Expert Opin Investig Drugs. 2023;32(10):901\u20138.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"789_CR126","doi-asserted-by":"publisher","first-page":"30","DOI":"10.25259\/IJDVL_15_2023","volume":"90","author":"MY Huang","year":"2023","unstructured":"Huang MY, Armstrong AW. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Indian J Dermatol Venereol Leprol. 2023;90(1):30\u201340.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"5","key":"789_CR127","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/13543784.2024.2337736","volume":"33","author":"EF Morand","year":"2024","unstructured":"Morand EF, Pike M, Merrill J, van Vollenhoven F, Werth R, Hobar VP. Plain Language summary of the PAISLEY study: Deucravacitinib as a treatment for people with systemic lupus erythematosus. Expert Opin Investig Drugs. 2024;33(5):431\u201340.","journal-title":"Expert Opin Investig Drugs"},{"key":"789_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.07.008","volume":"79","author":"Z Chen","year":"2024","unstructured":"Chen Z, Jiang P, Su D, Zhao Y, Zhang M. Therapeutic Inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease. Cytokine Growth Factor Rev. 2024;79:1\u201315.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"789_CR129","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/ecco-jcc\/jjad173","volume":"18","author":"DC Hindmarch","year":"2024","unstructured":"Hindmarch DC, Malashanka S, Shows DM, Clarke AS, Lord JD. Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of inflammatory bowel disease patients. J Crohns Colitis. 2024;18(4):628\u201337.","journal-title":"J Crohns Colitis"},{"key":"789_CR130","doi-asserted-by":"crossref","unstructured":"Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment. J Clin Med. 2021;10(23).","DOI":"10.3390\/jcm10235660"},{"issue":"11","key":"789_CR131","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1111\/jdv.18263","volume":"36","author":"L Zhang","year":"2022","unstructured":"Zhang L, Guo L, Wang L, Jiang X. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and Deucravacitinib in plaque psoriasis - A network meta-analysis. J Eur Acad Dermatol Venereol. 2022;36(11):1937\u201346.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"789_CR132","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/bjd\/ljae014","volume":"190","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024;190(5):668\u201379.","journal-title":"Br J Dermatol"},{"issue":"1","key":"789_CR133","doi-asserted-by":"publisher","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","volume":"35","author":"T Hagino","year":"2024","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of Deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatolog Treat. 2024;35(1):2307489.","journal-title":"J Dermatolog Treat"},{"key":"789_CR134","doi-asserted-by":"publisher","unstructured":"Zhao K, Xiao S, Zhao Y, Tu C. Real-world safety of deucravacitinib: insights from the food and drug administration adverse event reporting system. Int J Clin Pharm. 2025;47(5):1215\u201323. Epub 2025 Apr 9. https:\/\/doi.org\/10.1007\/s11096-025-01896-1","DOI":"10.1007\/s11096-025-01896-1"},{"key":"789_CR135","doi-asserted-by":"publisher","first-page":"1341632","DOI":"10.3389\/fimmu.2024.1341632","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Jiang G. Application of JAK inhibitors in Paradoxical reaction through immune-related dermatoses. Front Immunol. 2024;15:1341632.","journal-title":"Front Immunol"},{"issue":"1","key":"789_CR136","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/bjd\/ljad098","volume":"189","author":"MN Landis","year":"2023","unstructured":"Landis MN, Smith SR, Berstein G, Fetterly G, Ghosh P, Feng G, et al. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study. Br J Dermatol. 2023;189(1):33\u201341.","journal-title":"Br J Dermatol"},{"issue":"12","key":"789_CR137","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/cpdd.1163","volume":"11","author":"JH Hughes","year":"2022","unstructured":"Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population pharmacokinetics of oral brepocitinib in healthy volunteers and patients. Clin Pharmacol Drug Dev. 2022;11(12):1447\u201356.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"789_CR138","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1111\/bcp.15786","volume":"89","author":"R Qiu","year":"2023","unstructured":"Qiu R, Sharma R, Wei H, Kirkovsky L, Zhou Y, Martin DDA, et al. A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a. Br J Clin Pharmacol. 2023;89(10):3056\u201366.","journal-title":"Br J Clin Pharmacol"},{"key":"789_CR139","doi-asserted-by":"publisher","first-page":"1577115","DOI":"10.3389\/fimmu.2025.1577115","volume":"16","author":"Y Sun","year":"2025","unstructured":"Sun Y, Li Q, Zhang Y, Liu Y. Janus kinase inhibitors for alopecia areata: a review of clinical data. Front Immunol. 2025;16:1577115.","journal-title":"Front Immunol"},{"issue":"6","key":"789_CR140","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjd.21880","volume":"187","author":"SJ Lax","year":"2022","unstructured":"Lax SJ, Drucker AM. How will brepocitinib cream compare with established treatments for mild-to-moderate eczema? Br J Dermatol. 2022;187(6):838.","journal-title":"Br J Dermatol"},{"issue":"3","key":"789_CR141","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10928-024-09901-2","volume":"51","author":"N Tsamandouras","year":"2024","unstructured":"Tsamandouras N, Qiu R, Hughes JH, Sweeney K, Prybylski JP, Banfield C, et al. Employing zero-inflated beta distribution in an exposure-response analysis of TYK2\/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. J Pharmacokinet Pharmacodyn. 2024;51(3):265\u201377.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"789_CR142","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors Ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"789_CR143","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","volume":"86","author":"JG Krueger","year":"2022","unstructured":"Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase\u2013signal transducer and activator of transcription signaling and Inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148\u201357.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"789_CR144","first-page":"354","volume":"43","author":"JJ Paik","year":"2025","unstructured":"Paik JJ, Vencovsk\u00fd J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, et al. Brepocitinib, a potent and selective TYK2\/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2025;43(2):354\u201363.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"789_CR145","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","volume":"140","author":"SB Forman","year":"2020","unstructured":"Forman SB, Pariser DM, Poulin Y, Vincent MS, Gilbert SA, Kieras EM, et al. TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, Randomized, Double-Blind, Placebo-Controlled trial. J Invest Dermatol. 2020;140(12):2359\u2013e705.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"789_CR146","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bjd\/ljad157","volume":"189","author":"WC Cranwell","year":"2023","unstructured":"Cranwell WC, Sinclair RD. Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis? Br J Dermatol. 2023;189(1):9\u201310.","journal-title":"Br J Dermatol"},{"issue":"2","key":"789_CR147","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","volume":"13","author":"G Martin","year":"2023","unstructured":"Martin G. Novel therapies in plaque psoriasis: A review of tyrosine kinase 2 inhibitors. Dermatol Ther (Heidelb). 2023;13(2):417\u201335.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"789_CR148","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2147\/CCID.S433367","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, et al. JAK inhibitors in psoriatic disease. Clin Cosmet Investig Dermatol. 2023;16:3129\u201345.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"789_CR149","doi-asserted-by":"publisher","unstructured":"Sechi A, Song J, Dell\u2019Antonia M, Heidemeyer K, Piraccini BM, Starace M et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: a systematic review. J Eur Acad Dermatol Venereol. 2023. Online ahead of print. https:\/\/doi.org\/10.1111\/jdv.19090","DOI":"10.1111\/jdv.19090"},{"issue":"5","key":"789_CR150","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40261-023-01260-z","volume":"43","author":"M Papierzewska","year":"2023","unstructured":"Papierzewska M, Wa\u015bkiel-Burnat A, Rudnicka L. Safety of Janus kinase inhibitors in patients with alopecia areata: A systematic review. Clin Drug Investig. 2023;43(5):325\u201334.","journal-title":"Clin Drug Investig"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00789-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00789-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00789-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:03:22Z","timestamp":1764119002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00789-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":150,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00789-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}